A pilot, open label, single dose, randomized, four-period, four-sequence, four-treatment crossover, comparative bioavailability study of UDCA PMCS 500 mg formulation 1 film-coated tablets (test 1 formulation), and UDCA PMCS 500 mg formulation 2 film-coated tablets (test 2 formulation), and UDCA PMCS 500 mg formulation 3 film-coated tablets (test 3 formulation), and reference formulation in healthy, male and female volunteers under fasting conditions.

2024-519920-26-00 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 20 Feb 2025 · End 14 Apr 2025 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 24
Countries 1
Sites 1

UDCA causes a reduction in cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and reducing cholesterol secretion into the bile. Presumably, cholesterol gallstones are gradually dissolved by dispersion of the cholesterol and formation of liquid crystals.

Key facts

Sponsor
Cepha s.r.o., PRO.MED.CS Praha a.s.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
20 Feb 2025 → 14 Apr 2025
Decision date (initial)
2025-02-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

UDCA causes a reduction in cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and reducing cholesterol secretion into the bile. Presumably, cholesterol gallstones are gradually dissolved by dispersion of the cholesterol and formation of liquid crystals.

VersionLevelCodeTermSystem organ class
20.0 LLT 10017650 Gallstones 10019805
20.1 LLT 10004671 Biliary sludge 10019805

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Cepha s.r.o.

Sponsor organisation
Cepha s.r.o.
Address
Komenskeho 19, Severni Predmesti Severni Predmesti
City
Plzen 1
Postcode
323 00
Country
Czechia

Scientific contact point

Organisation
Cepha s.r.o.
Contact name
Clinical

Public contact point

Organisation
Cepha s.r.o.
Contact name
Clinical

PRO.MED.CS Praha a.s.

Sponsor organisation
PRO.MED.CS Praha a.s.
Address
Telcska 377/1, Michle Michle
City
Prague
Postcode
140 00
Country
Czechia

Scientific contact point

Organisation
PRO.MED.CS Praha a.s.
Contact name
Jan Sixta

Public contact point

Organisation
PRO.MED.CS Praha a.s.
Contact name
Jan Sixta

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 24 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Cepha s.r.o.
clinic, Komenskeho 19, Severni Predmesti, Plzen 1

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2025-02-20 2025-04-14 2025-02-20 2025-02-27

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-01-07 Czechia Acceptable
2025-02-12
2025-02-12